Abstract:Importance: Multiple paclitaxel-based regimens are widely used in chemoradiation therapy against esophageal cancer, including regimens combining paclitaxel with fluorouracil, cisplatin, and carboplatin. However, which among these 3 regimens provides the best prognosis with minimum adverse events is still unknown.Objective: To compare the efficacy and adverse events of fluorouracil, cisplatin, and carboplatin in definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma (ESCC).Design, Setting, and Participants: This randomized clinical trial of patients with ESCC was conducted in 11 treatment centers in China. Eligible patients were aged 18 to 75 years and had histologically confirmed ESCC stages IIa to IVa with no prior treatment, Eastern Cooperative Oncology Group performance status of 2 or lower, and adequate organ functions. The study was conducted between July 2015 and February 2018, and the cutoff date for data analysis was August 31, 2020.Interventions: Patients with locally advanced ESCC were randomly assigned (1:1:1) to groups combining paclitaxel treatment with fluorouracil, cisplatin, or carboplatin. Patients in the cisplatin group were treated with 2 cycles of concurrent chemoradiotherapy followed by 2 cycles of consolidation chemotherapy with monthly paclitaxel plus cisplatin. For the fluorouracil group, patients were administered 6 cycles of weekly paclitaxel plus fluorouracil in concurrent chemoradiotherapy followed by 2 cycles of monthly paclitaxel plus fluorouracil in consolidation chemotherapy. Patients in the carboplatin group were treated with 6 cycles of weekly paclitaxel plus carboplatin in concurrent chemoradiotherapy followed by 2 cycles of monthly paclitaxel plus carboplatin in consolidation chemotherapy. All patients received radiotherapy of 61.2 Gy delivered in 34 fractions.Main Outcomes and Measures: The primary end point was overall survival (OS). The secondary end points were progression-free survival and adverse events.Results: Overall, 321 patients (median [IQR] age, 64 years [59-69 years]; 248 [77.3%] men) with ESCC from 11 centers were randomized into fluorouracil, cisplatin, or carboplatin groups between July 2015 and February 2018. Over a median (IQR) follow-up time of surviving patients of 46.0 months (36.6-53.0 months), the 3-year OS rates were 57.2% in the fluorouracil group, 60.1% in the cisplatin group, and 56.5% in the carboplatin group, respectively (fluorouracil vs cisplatin: HR, 1.06; 95% CI, 0.71-1.60; P = .77; fluorouracil vs carboplatin: HR, 0.94; 95% CI, 0.63-1.40; P = .77). The cisplatin group had significantly higher incidences of acute grade 3 or 4 neutropenia (69 events [60.8%] vs 19 [17.8%] for fluorouracil and 37 [34.6%] carboplatin; P < .001), thrombocytopenia (14 events [13.1%] vs 4 [3.7%] for fluorouracil and 5 [4.7%] for carboplatin; P = .01), anemia (50 events above grade 2 [46.7%] vs 25 [23.4%] for fluorouracil and 37 [34.6%] for carboplatin; P = .35), fatigue (11 events [10.3%] vs 2 [1.9%] for fluorouracil and 1 [0.9%] carboplatin; P = .007), and vomiting (17 events above grade 2 [15.9%] vs 3 [2.8%] for fluorouracil and 5 [4.7%] for carboplatin; P < .001) than the other 2 groups.Conclusions and Relevance: In this randomized clinical trial, paclitaxel plus fluorouracil did not show OS superiority over paclitaxel plus cisplatin or paclitaxel plus carboplatin regimens in definitive chemoradiation in patients with locally advanced ESCC. Higher rates of hematologic and gastrointestinal toxic effects were reported in the cisplatin group compared with those in the fluorouracil or carboplatin groups.Trial Registration: ClinicalTrials.gov Identifier: NCT02459457.

High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial

Phase I Study of Dose-Escalated Intensity-Modulated Hyperfractionated Radiation Therapy (HFRT) Boost with Concurrent Paclitaxel (P) and Carboplatin (C) to Gross Tumor Volume (GTV) Following Standard-Dose Chemoradiotherapy (SCRT) for Advanced Esophageal Ca

Phase III Randomized Study of Preoperative Versus Postoperative Chemoradiotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial

High Versus Standard Radiation Dose of Definitive Chemoradiotherapy Combined with Immunotherapy for Inoperable Esophageal Squamous Cell Carcinoma: A Multicenter Propensity Score Matching Analysis.

A Randomized Phase II/III Study of Paclitaxel/cisplatin Versus Cisplatin/5-Fluorouracil in Neoadjuvant Chemoradiotherapy (CRT) Followed by Surgery for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC).

A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma

Improved Local Control by Surgery and Paclitaxel-Based Chemoradiation for Esophageal Squamous Cell Carcinoma: Results of a Retrospective Non-Randomized Study.

Preliminary Results of a Multicenter, Randomized, Prospective Study Evaluating the Optimal Radiation Dose of Definitive Concurrent Chemoradiation for Inoperable Esophageal Squamous Cell Carcinoma

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer A Randomized Clinical Trial

Intensity-Modulated Radiotherapy Versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities

A Multi-Center, Randomized, Prospective Study Evaluating The Optimal Radiation Dose Of Definitive Concurrent Chemoradiation For Inoperable Esophageal Squamous Cell Carcinoma.

Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer

Phase 2 Study of Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable Locally Advanced Esophageal Squamous Cell Carcinoma

Do higher radiation doses improve survival for cervical esophageal squamous cell cancer patients treated with definitive chemoradiotherapy using intensity-modulated radiotherapy? A propensity-score matched analysis

[A multicenter randomized prospective study of concurrent chemoradiation with 60 Gy versus 50 Gy for inoperable esophageal squamous cell carcinoma].

Safety Results of a Phase III Randomized Trial of Comparison of Three Paclitaxel-Based Regimens Concurrent with Radiotherapy for Patients with Local Advanced Esophageal Squamous Cell Carcinoma (Eso-Shanghai 2)

Long-Term Outcomes of Three-Dimensional Conformal Radiation Therapy Without Chemotherapy for Esophageal Squamous Cell Carcinoma: A Final Report of a Phase 2 Study

Final Results of a Phase 3 Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma (Eso-Shanghai 1).

Dose-Escalated Definitive Chemoradiotherapy with Intensity-Modulated Radiation Therapy Versus Esophagectomy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma